AB0667 THE EFFICACY OF FILGOTINIB IN RHEUMATOID ARTHRITIS MAY BE TIME-DEPENDENT. (IN VIEW OF THE HILL COEFFICIENT OF FILGOTINIB)
Authors: T. Yoshikawa, T. Abe, M. Tamura, T. Furukawa, T. Hashimoto, N. Azuma, K. Matsui
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Janus kinase inhibitors (JAKi) represent a novel class of oral targeted disease-modifying drugs, heralding a recent revolution in the therapeutic landscape for rheumatoid arthritis (RA) and other immune-mediated conditions. These inhibitors, which can complement or even replace conventional and biological drugs, operate through a distinctive mechanism involving intracellular disruption of the JAK-STAT pathway—a pivotal player in the immune response. The Hill coefficient (H) serves to describe the sigmoidicity of a drug's concentration-response curve. When H &gt; 2.0, a "time-dependent" effect is observed, where the critical factor is not the peak drug concentration but the crossing of a threshold beneath which the effect becomes negligible. The prolonged serum concentration above this threshold correlates with a more pronounced effect. Conversely, when H &lt; 2.0, a "concentration-dependent" effect emerges, with the peak concentration holding significance [1]. In the report by Chimalakonda A et al [2], the H for the inhibitory effect of JAK1/3 in tofacitinib, baricitinib, and upadacitinib ranged from 1.0-1.3. For JAK1 inhibition in filgotinib (FIL), the H was nearly 2 [3]. Intriguingly, in a phase II study, FIL at 100 mg BID demonstrated a tendency to be more effective than FIL at 200 mg QD after 12 weeks of treatment [4]. However, the time-dependency of FIL's effect on rheumatoid arthritis remains unclear. <h3>Objectives:</h3> The objective of this investigation is to assess whether the impact of FIL on rheumatoid arthritis exhibits time-dependent characteristics. <h3>Methods:</h3> This constituted a retrospective, observational study involving 25 patients diagnosed with rheumatoid arthritis (RA) who met the 2010 American College of Rheumatology (ACR)/EULAR classification criteria. These patients were prescribed FIL and underwent a minimum 12-week follow-up at our hospital from November 2020 to October 2023. The efficacy of FIL was assessed based on the EULAR response at 12-week treatment, with concurrent measurement of the change in DAS28-CRP. Patients were categorized into three groups based on renal function and FIL dosage: FIL 200 mg group [FIL200], FIL 100 mg with chronic kidney disease (CKD) (eGFR &lt; 60 ml/min/1.73m<sup>2</sup>) [FIL100CKD], and FIL 100 mg without CKD [FIL100]. <h3>Results:</h3> The median age of the patients was 69.0 years (IQR: 61.0-76.0), and the median disease duration was 156 months (102-180). The median DAS28-CRP was 3.60 (3.16-4.49). Comparing the FIL100CKD group to the FIL200 group, the former exhibited a higher median age (80.0 vs. 73.0 year, P&lt;0.05). However, other patient backgrounds showed no statistically significant differences. No significant variations were observed in the number of concomitant MTX, other csDMARDs, or prednisolone among the three groups. But, there was a tendency towards fewer patients being biologics- and JAKi-naive in the FIL200 group (FIL100 group; 60.0%, FIL100CKD group; 66.7% and FIL200 group; 14.3%, respectively). In terms of treatment outcomes, the EULAR response and ΔDAS28-CRP at 12 weeks tended to be higher in the FIL100, FIL100CKD, and FIL200 groups, in that sequential order (Figure 1). <h3>Conclusion:</h3> FIL exhibits a Hill coefficient close to 2, implying a time-dependent pharmacodynamic effect rather than concentration dependence. In cases with eGFR &lt;60, the time above IC5 for JAK1 is extended (FIL100; approximately 6 hours, FIL100CKD; approximately 8 hours, FIL200; approximately 9.5 hours) [5,6]. Clinical data derived from the current study imply that the efficacy of FIL is time-dependent. Further studies are needed to confirm this. <h3>REFERENCES:</h3> [1] Czock D, Keller F. J Pharmacokinet Phar. 2007;34(6):727–51. [2] Chimalakonda A, et al. Dermatology Ther. 2021;11(5):1763–76. [3] Namour F, et al. Clin Pharmacokinet. 2015;54(8):859–74. [4] Westhovens R, et al. Ann Rheum Dis. 2017;76(6):998. [5] Namour F, et al. Brit J Clin Ph REFERENCES armaco. 2018;84(12):2779–89. [6] Veeravalli V, et al. Drug Safety. 2020;1–15. 12W EULAR response <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>